Featured Articles

  1. Navigating AI's Impact On Life Sciences And Patent Law 3/26/2025

    AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.

  2. How To Get Ready For The Talent Migration Between Pharma And Biotech 3/25/2025

    A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in Big Pharma and biotech culture and expectations to be successful.

  3. Resetting The Immune System For Lasting Remission 3/19/2025

    Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and inflammatory conditions, using novel targets and improved modalities.

  4. Testing Federal Healthcare Laws: Risks In Genetic-Testing Programs 3/13/2025

    Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly. Experts at Morrison Foerster share best practices for compliance.

  5. Pharma's Guide To Making Health Communications Land Well 3/11/2025

    New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must also be credible and consumable, writes Michelle Bridenbaker.

  6. AI In A Time Of Uncertainty: Key Strategies To Enable Flexibility 3/4/2025

    Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI systems are necessary for life science organizations to keep pace with change.

  7. A CEO With A General Counsel's Perspective 2/28/2025

    LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous perspective on the CEO role.

  8. Interchangeability In Leadership: A Career Built On Versatility 2/27/2025

    Adaptability serves as the foundation for lasting career success, shaping leaders who can thrive in an ever-changing business landscape, explains Mary Beth Sandin.

  9. An Updated View of The Federal Segment: DHA Formulary Management 2/25/2025

    Part two of a three-part series aimed at helping drug and device manufacturers better navigate and understand the Veterans Affairs and Department of Defense health systems.

  10. FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance 2/21/2025

    Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order. That doesn't mean biopharmaceutical companies can backslide on compliance in global markets.